This database contains 457 studies, archived under the term: "drug therapy"
Click here to filter this large number of results.
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease
Blennow, Kaj,
Zetterberg, Henrik,
Rinne, Juha O.,
Salloway, Stephen,
Wei, Jenny,
Black, Ronald,
Grundman, Michael,
Liu, Enchi
Background: Given the slow and variable clinical course of Alzheimer disease, very large and extended clinical trials are needed to identify a beneficial clinical effect of disease-modifying treatments. Therefore, biomarkers are essential to prove that an anti-β-amyloid (Aβ) drug candidate affects both Aβ metabolism and plaque load as well as downstream pathogenic mechanisms.; Objective: To […]
A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s disease
We examined the effects of 3 dosages of pridopidine, a dopamine-stabilizing compound, on motor function and other features of Huntington’s disease, with additional evaluation of its safety and tolerability. This was a randomized, double-blind, placebo-controlled trial in outpatient neurology clinics at 27 sites in the United States and Canada. Two hundred twenty-seven subjects enrolled from […]
Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer’s disease
Kume, Kazumasa,
Hanyu, Haruo,
Sakurai, Hirofumi,
Takada, Yusuke,
Onuma, Takeshi,
Iwamoto, Toshihiko
Aim: Recent studies have shown that some antihypertensive medications are associated with a significant reduction in the incidence of Alzheimer’s disease (AD). However, it remains uncertain whether antihypertensive drugs may have a preventive effect on cognitive decline in patients with AD. We investigated the effects of telmisartan, an angiotensin II type 1 receptor blocker with […]
Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
Farlow, Martin,
Arnold, Steven E.,
van Dyck, Christopher H.,
Aisen, Paul S,
Snider, B. Joy,
Porsteinsson, Anton P.,
Friedrich, Stuart,
Dean, Robert A.,
Gonzales, Celedon,
Sethuraman, Gopalan,
Demattos, Ronald B.,
Mohs, Richard,
Paul, Steven M.,
Siemers, Eric R.
Objectives: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of 12 weekly infusions of solanezumab, an anti-β-amyloid (Aβ) antibody, in patients with mild-to-moderate Alzheimer’s disease. Cognitive measures were also obtained.; Methods: In this phase 2, randomized, double-blind, placebo-controlled clinical trial, 52 patients with Alzheimer’s disease received placebo or antibody (100 mg every 4 weeks, 100 […]
Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine
Iwasaki, Koh,
Kosaka, Kenji,
Mori, Hideo,
Okitsu, Reina,
Furukawa, Katsutoshi,
Manabe, Yuta,
Yoshita, Mitsuhiro,
Kanamori, Aya,
Ito, Nobuo,
Wada, Kenji,
Kitayama, Michio,
Horiguchi, Jun,
Yamaguchi, Shuhei,
Takayama, Shin,
Fukuhara, Ryuji,
Ouma, Shinji,
Nakano, Seigo,
Hashimoto, Mamoru,
Kinoshita, Toru
Background: This multicentre open-label trial examined the efficacy and safety of the traditional Japanese medicine, or Kampo medicine, yokukansan (YKS), for behavioural and psychological symptoms of dementia (BPSD) in patients with dementia with Lewy bodies.; Methods: Sixty-three dementia with Lewy bodies patients with probable BPSD (M:W, 30:33; mean age, 78.2±5.8 years) were enrolled and treated […]
Effect of six months of treatment with V0191 in patients with suspected prodromal Alzheimer’s disease
Dubois, Bruno,
Zaim, Mohammed,
Touchon, Jacques,
Vellas, Bruno,
Robert, Philippe,
Murphy, Michael F.,
Pujadas-Navinés, Francesc,
Rainer, Michael,
Soininen, Hilkka,
Riordan, Henry J.,
Kanony-Truc, Claire
New criteria related to prodromal Alzheimer’s disease (AD) have been proposed to overcome the issue of heterogeneity of patients with mild cognitive impairment (MCI) and to better define patients in early stage AD. Only few therapeutic trials, if any, have been reported using this newly defined population. The objective of this study was to assess […]
Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial
Newhouse, P.,
Kellar, K.,
Aisen, P.,
White, H.,
Wesnes, K.,
Coderre, E.,
Pfaff, A.,
Wilkins, H.,
Howard, D.,
Levin, E. D.
Objective: To preliminarily assess the safety and efficacy of transdermal nicotine therapy on cognitive performance and clinical status in subjects with mild cognitive impairment (MCI).; Methods: Nonsmoking subjects with amnestic MCI were randomized to transdermal nicotine (15 mg per day or placebo) for 6 months. Primary outcome variables were attentional improvement assessed with Connors Continuous […]
Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial
Objective: Because cholinergic deficits are prominent in dementia with Lewy bodies (DLB), we investigated the effects of a cholinesterase inhibitor, donepezil, in such patients in a randomized, double-blind, placebo-controlled exploratory phase 2 trial.; Methods: One-hundred forty patients with DLB, recruited from 48 specialty centers in Japan, were randomly assigned to receive placebo or 3, 5, […]
Effect of second-generation antipsychotics on caregiver burden in Alzheimer’s disease
Mohamed, Somaia,
Rosenheck, Robert,
Lyketsos, Constantine G.,
Kaczynski, Richard,
Sultzer, David L.,
Schneider, Lon S.
Background: Alzheimer’s disease (AD) imposes a severe burden upon patients and their caregivers. Severity of psychiatric symptoms and behavioral disturbances is an important determinant of caregivers’ experience of burden. These symptoms may be improved with atypical antipsychotic treatment.; Objective: Data from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) trial were used to evaluate […]